The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT)

NCT01265498 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

283

Enrollment

NIH

Sponsor class

Conditions

Nonalcoholic Fatty Liver Disease (NAFLD)
Nonalcoholic Steatohepatitis (NASH)

Interventions

DRUG: obeticholic acid
DRUG: placebo

Sponsor

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)